Details

Autor(en) / Beteiligte

• Levin, Myron J.
• Smith, Jeffrey G.
• Kaufhold, Robin M.
• Barber, Debra
• Hayward, Anthony R.
• Chan, Christina Y.
• Chan, Ivan S. F.
• Li, David J. J.
• Wang, William
• Keller, Paul M.
• Shaw, Alan
• Silber, Jeffrey L.
• Schlienger, Katia
• Chalikonda, Ira
• Vessey, S. J. R.
• Caulfield, Michael J.

Titel

Decline in Varicella-Zoster Virus (VZV)–Specific Cell-Mediated Immunity with Increasing Age and Boosting with a High-Dose VZV Vaccine

Ist Teil von

• The Journal of infectious diseases, 2003-11, Vol.188 (9), p.1336-1344

Ort / Verlag

Chicago, IL: The University of Chicago Press

Erscheinungsjahr

2003

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• The safety and immunogenecity of a booster dose of live attenuated varicella-zoster virus (VZV) vaccine was evaluated in 196 healthy subjects, ⩾60 years old, who had already received a VZV vaccine >5 years before. This repeat booster dose was well tolerated. Cell-mediated immunity (CMI) to VZV was measured by an interferon-γ (IFN-γ) enzyme-linked immunosorbent spot-forming cell (ELISPOT) assay and a limiting dilution responder cell frequency (RCF) assay. Prevaccination responses decreased as a function of increasing age but were detectable in all subjects by use of the IFN-γ ELISPOT assay. In most subjects, VZV-specific CMI was increased at 6 weeks postvaccination. The magnitude of the vaccine-induced IFN-γ ELISPOT response was inversely related to prevaccination values. Although there was a significant correlation between the IFN-γ ELISPOT and RCF assays, the ELISPOT assay had greater sensitivity and a wider dynamic range. A live attenuated VZV vaccine is safe and immunogenic in an elderly population, and the vaccine-induced immunity may be monitored by the IFN-γ ELISPOT assay